<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>BiG生物创新社 | wechat-feeds</title><link>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</link><description>BiG, Biologics Innovation Group. To nurture an Eco-system for Biologics innovation and imprint China on Global map.</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 16 May 2021 15:27:36 +0800</pubDate><image><url>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</url><title>BiG生物创新社 | wechat-feeds</title><link>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>一路高歌的康方：梅花香自苦寒来！</title><link>https://mp.weixin.qq.com/s/Px4UfCEWGSHLEwhpqcouGQ</link><description></description><content:encoded><![CDATA[一路高歌的康方：梅花香自苦寒来！]]></content:encoded><pubDate>Sun, 16 May 2021 14:15:39 +0800</pubDate></item><item><title>合成致死赛道的后起之秀：PRMT5/MAT2A抑制剂</title><link>https://mp.weixin.qq.com/s/1KliSNGNF9JzGSb8QxyrPQ</link><description></description><content:encoded><![CDATA[合成致死赛道的后起之秀：PRMT5/MAT2A抑制剂]]></content:encoded><pubDate>Sat, 15 May 2021 08:27:10 +0800</pubDate></item><item><title>群雄逐鹿，东海论药｜BiG七周年大咖云集</title><link>https://mp.weixin.qq.com/s/_TmrTolxTxDFguqpFst_yQ</link><description></description><content:encoded><![CDATA[群雄逐鹿，东海论药｜BiG七周年大咖云集]]></content:encoded><pubDate>Fri, 14 May 2021 16:38:03 +0800</pubDate></item><item><title>深度｜自免与炎症治疗市场前景与研发趋势分析</title><link>https://mp.weixin.qq.com/s/XkhEy97msiocHb1HHI1wYw</link><description></description><content:encoded><![CDATA[深度｜自免与炎症治疗市场前景与研发趋势分析]]></content:encoded><pubDate>Fri, 14 May 2021 16:38:03 +0800</pubDate></item><item><title>毒性是关键！TROP-2 ADC药物的临床实验总览</title><link>https://mp.weixin.qq.com/s/hQQFvPfh3OlabO0fMw9i4g</link><description></description><content:encoded><![CDATA[毒性是关键！TROP-2 ADC药物的临床实验总览]]></content:encoded><pubDate>Fri, 14 May 2021 16:38:03 +0800</pubDate></item><item><title>免疫检查点与自身免疫性疾病</title><link>https://mp.weixin.qq.com/s/dCRVIcgWcbDcN1eMBhp-pA</link><description></description><content:encoded><![CDATA[免疫检查点与自身免疫性疾病]]></content:encoded><pubDate>Thu, 13 May 2021 10:05:16 +0800</pubDate></item><item><title>大手笔！科望今日宣布完成1.05亿美元C轮融资</title><link>https://mp.weixin.qq.com/s/ClfBzXDbWH5clpWInl6A1A</link><description></description><content:encoded><![CDATA[大手笔！科望今日宣布完成1.05亿美元C轮融资]]></content:encoded><pubDate>Thu, 13 May 2021 10:05:16 +0800</pubDate></item><item><title>新江湖｜张彦丰、刘帆、龚东屹、姜子瑜加入BiG！</title><link>https://mp.weixin.qq.com/s/RKZVIWWvZLqpDt5AOtr0tg</link><description></description><content:encoded><![CDATA[新江湖｜张彦丰、刘帆、龚东屹、姜子瑜加入BiG！]]></content:encoded><pubDate>Thu, 13 May 2021 10:05:16 +0800</pubDate></item><item><title>起死回生？CD28双抗+CD3双抗=CAR-T？</title><link>https://mp.weixin.qq.com/s/SRMD12hjbaVZfEka9wH2XQ</link><description></description><content:encoded><![CDATA[起死回生？CD28双抗+CD3双抗=CAR-T？]]></content:encoded><pubDate>Wed, 12 May 2021 16:23:27 +0800</pubDate></item><item><title>星辰亲吻大海，新药碰撞艺术｜BiG慈善之夜</title><link>https://mp.weixin.qq.com/s/5UKL2feMkMApxobrVz6SCg</link><description></description><content:encoded><![CDATA[星辰亲吻大海，新药碰撞艺术｜BiG慈善之夜]]></content:encoded><pubDate>Wed, 12 May 2021 16:23:27 +0800</pubDate></item><item><title>新江湖｜薛彤彤、冉飞武、邓晓宇、张宏恺加入BiG！</title><link>https://mp.weixin.qq.com/s/2K3cAEY0XeWtFPsfrcYCAQ</link><description></description><content:encoded><![CDATA[新江湖｜薛彤彤、冉飞武、邓晓宇、张宏恺加入BiG！]]></content:encoded><pubDate>Wed, 12 May 2021 16:23:27 +0800</pubDate></item><item><title>Treg的未来：CAR-Treg</title><link>https://mp.weixin.qq.com/s/8XulgQ8SIvFAVm_MKDnE9w</link><description></description><content:encoded><![CDATA[Treg的未来：CAR-Treg]]></content:encoded><pubDate>Sun, 09 May 2021 20:42:19 +0800</pubDate></item><item><title>BiG招募︱记者编辑，专栏作者</title><link>https://mp.weixin.qq.com/s/DpXtbeKRGGFhRvGJbuwiEg</link><description></description><content:encoded><![CDATA[BiG招募︱记者编辑，专栏作者]]></content:encoded><pubDate>Sun, 09 May 2021 20:42:19 +0800</pubDate></item><item><title>信达生物：生亦逢时，成长中的Pharma！</title><link>https://mp.weixin.qq.com/s/kxvz5Sr4KkncNwWwTSXB6g</link><description></description><content:encoded><![CDATA[信达生物：生亦逢时，成长中的Pharma！]]></content:encoded><pubDate>Sun, 09 May 2021 19:28:29 +0800</pubDate></item><item><title>爆款是如何诞生的？靶向IL-4Rα重磅药Dupixent</title><link>https://mp.weixin.qq.com/s/atUmrTQPk5oLvQdA_VyFZw</link><description></description><content:encoded><![CDATA[爆款是如何诞生的？靶向IL-4Rα重磅药Dupixent]]></content:encoded><pubDate>Sat, 08 May 2021 16:01:03 +0800</pubDate></item><item><title>吉凯基因IPO刷屏背后！技术全梳理</title><link>https://mp.weixin.qq.com/s/c72Q6D0DC8-zb1JWbD2Xpg</link><description></description><content:encoded><![CDATA[吉凯基因IPO刷屏背后！技术全梳理]]></content:encoded><pubDate>Sat, 08 May 2021 16:01:03 +0800</pubDate></item><item><title>盘点！抗癌药物飞速发展的五年</title><link>https://mp.weixin.qq.com/s/3X5Ricb9LoWmriqD1Zx1Zw</link><description></description><content:encoded><![CDATA[盘点！抗癌药物飞速发展的五年]]></content:encoded><pubDate>Fri, 07 May 2021 10:28:58 +0800</pubDate></item><item><title>龙头难以撼动！PD-(L)1后来者的错位竞争机会</title><link>https://mp.weixin.qq.com/s/khAphyyrzCJj30rMLQ_9zg</link><description></description><content:encoded><![CDATA[龙头难以撼动！PD-(L)1后来者的错位竞争机会]]></content:encoded><pubDate>Fri, 07 May 2021 10:28:58 +0800</pubDate></item><item><title>百济：优秀的Biotech，坎坷的Big-Pharma</title><link>https://mp.weixin.qq.com/s/d-O133CgU5f3WI_Di8rFhw</link><description></description><content:encoded><![CDATA[百济：优秀的Biotech，坎坷的Big-Pharma]]></content:encoded><pubDate>Thu, 06 May 2021 11:08:09 +0800</pubDate></item><item><title>“万抗”恒瑞的研发管线</title><link>https://mp.weixin.qq.com/s/2vzZgAgVYXQFbQ7F6q3Yog</link><description></description><content:encoded><![CDATA[“万抗”恒瑞的研发管线]]></content:encoded><pubDate>Thu, 06 May 2021 11:08:09 +0800</pubDate></item></channel></rss>